Sir, HIV-1 Vif protein counteracts the lethal hypermutation produced by the cellular antiviral factor APOBEC3G (A3G) in HIV-1. 1 This effect consists of a cytidine deamination of the HIV-1 cDNA that results in guanosine to adenosine (G-to-A) substitutions in the proviral sequences 2 in a GG-to-GA dinucleotide context. However, in defective Vif alleles these G-to-A substitutions could benefit the virus, promoting sequence diversification 3 even in drug resistance sites, and therefore accelerate the evolution of resistance and immune escape. It would represent a new mechanism of viral escape from antiretrovirals and a suitable target for drug development. 4 In this context, the mutation Vif-K22H (located in the Vif -A3G interaction domain) has been recently identified as a key mutation to trigger this mechanism in subjects under therapy failure. 5 However, all the described Vif-K22H samples were subtype B. Most studies are based on this subtype because it is prevalent in developed regions, despite the worldwide predominance of HIV-1 non-B variants, a term that includes the remaining subtypes and inter-subtype recombinants.
Here we analyse the presence of Vif-K22H in the most prevalent HIV-1 non-B subtypes and recombinants, which, up to now, is still unknown. All HIV-1 vif sequences (n¼ 2895) ascribed to pure subtypes and recombinants CRF01_AE and CRF02_AG were downloaded from the Los Alamos National Laboratory Database (LANL-DB) in March 2010: 143 A1; 5 A2; 1690 B; 546 C; 91 D; 36 F1; 4 F2; 30 G; 4 H; 3 J; 2 K; 242 CRF01_AE; and 99 CRF02_AG. Nucleotide and amino acid variability in Vif-22 across all HIV-1 studied subtypes and recombinants was identified and compared (Table 1) . Lysine was the wild-type residue at Vif-22 in subtypes B, D, H, J and K, and sub-subtype F1 ('K22 variants'). However, the wildtype residue was asparagine in the remaining variants (A1, A2, C, F2, G, CRF01_AE and CRF02_AG; 'N22 variants'). Interestingly, the change to histidine (codified by codon CAC or CAT) is different according to the original residue. Its emergence requires two changes from K22 (mostly codified by AAA), but only requires a single change from N22 as the wild-type residue (AAC or AAT). We found a significant 2-fold higher H22 prevalence in N22 variants compared with K22 variants (6.4% versus 2.7%; P,0.01), especially in subtype A1 (17.5%) and recombinants CRF02_AG (11.1%) and CRF01_AE (8.7%). In contrast, subtype C showed a low H22 prevalence (1.6%). Whether this difference is due to the fact that subtype C is the only N22 variant with AAT as the wild-type codon codifying asparagine, unlike the remaining N22 variants (codon AAC), remains to be clarified by additional analysis.
In isolates with both pol and vif sequences from the same specimen available in the LANL-DB (n¼ 1791), the pol sequence was also downloaded to assess the presence of drug-resistance mutations in protease (PR) and/or reverse transcriptase (RT), which could have been caused by the effect of A3G, i.e. those produced by G-to-A substitutions in a GG-to-GA dinucleotide context: G16E, D30N, M36I, M46I and G73S in PR; and D67N, M184I and G190S/E in RT. The presence of these mutations was compared in sequences with (n¼ 75) or without (n¼ 1716) the Vif-22H mutation. The prevalence of the PR mutations M36I (81.3% versus 60%; P,0.01) and M46I (8% versus 2.2%; P,0.01) was significantly higher in the Vif-H22 isolates, but the remaining mutations were not significantly different when comparing the two groups: 12% versus 8.3% for G16E, 0% versus 0.8% for D30N and 0% versus 0.2% for G73S in PR; and 0% versus 2.2% for D67N, 2.7% versus 0.2% for M184I and 0% versus 0.9% for G190S/E in RT.
PR-M36I, a minor resistance mutation to protease inhibitors (PIs) according to the International AIDS Society-USA, is also the wild-type residue in most non-B variants but not in subtype B. Nevertheless, an increase in this change has been reported among Vif-H22 subtype B viruses 5 and it is possible that its higher prevalence among Vif-H22 variants is not due just to HIV-1 clade. In fact, polymorphisms in PR-36 play a role in the development of PI resistance and replication capacity depending on viral subtype. 6 On the other hand, whether or not the major PI-resistance mutation M46I can appear more quickly in vivo after virological failure among HIV-1 non-B variants carrying Vif-N22 as wild-type remains to be clarified.
In conclusion, we observed that some of the most prevalent HIV-1 non-B variants (A1, A2, C, F2, G, CRF01_AE and CRF02_ AG, which altogether represent over three-quarters of global infections) could follow a shorter route to acquire Vif-22H. This could help the virus to evade therapy through partial hypermutation in resistance-associated positions in the presence of antiretrovirals. Thus, the HIV-1 clade could play a key role in the development of this novel mechanism of resistance to antiretrovirals. However, future studies are needed to understand the predictive value of Vif mutations for treatment failure and establish a causal correlation between Vif function and drug escape during HIV-1 replication. 
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